Keywords: suspends, rescriptor, trial, pharmacia, upjohn, halted, its
P&U Suspends Rescriptor Trial
Article | 05 February 1998
Pharmacia & Upjohn has halted a trial of its non-nucleoside reversetranscriptase inhibitor Rescriptor (delavirdine) because an interim analysis has demonstrated statistically-significant ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
